{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:43:29Z","timestamp":1759938209319,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The morbidity and mortality rates of human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfection are higher than that of either infection alone. Outcomes and the virological response to antiretrovirals (combination antiretroviral therapy, cART) were explored in HIV\/HBV subjects in a cohort of Italian patients treated with cART. A single-center retrospective analysis of patients enrolled from January 2007 to June 2018 was conducted by grouping patients by HBV status and recording baseline viro-immunological features, the history of virological failure, the efficacy of cART in achieving HIV viral undetectability, viral blip detection and viral rebound on follow up. Among 231 enrolled patients, 10 (4.3%) were HBV surface (s) antigen (HBsAg)-positive, 85 (36.8%) were positive for antibodies to HBV c antigen (HBcAb) and with or without antibodies to HBV s antigen (HBsAb), and 136 were (58.9%) HBV-negative. At baseline, HBcAb\/HBsAb<jats:sup>+\/\u2212<\/jats:sup>-positive patients had lower CD4+ cell counts and CD4+ nadirs (188 cell\/mmc, IQR 78\u2013334, p\u2009=\u20090.02 and 176 cell\/mmc, IQR 52\u2013284, p\u2009=\u20090,001, respectively). There were significantly higher numbers of AIDS and non-AIDS events in the HBcAb<jats:sup>+<\/jats:sup>\/HBsAb<jats:sup>+\/\u2212<\/jats:sup>-positive subjects than in the HBV-negative patients (41.1% vs 19.1%, p\u2009=\u20090.002 and 56.5% vs 28.7%, respectively, p\u2009\u2264\u20090.0001); additionally, HIV viremia undetectability was achieved a significantly longer time after cART was begun in the former than in the latter population (6 vs 4 months, p\u2009=\u20090.0001). Cox multivariable analysis confirmed that after starting cART, an HBcAb<jats:sup>+<\/jats:sup>\/HBsAb<jats:sup>+\/\u2212<\/jats:sup>-positive status is a risk factor for a lower odds of achieving virological success and a higher risk of experiencing virological rebound (AHR 0.63, CI 95% 0.46\u20130.87, p\u2009=\u20090.004 and AHR 2.52, CI 95% 1.09\u20135.80, p\u2009=\u20090.030). HBcAb-positive status resulted in a delay in achieving HIV\u2009&lt;\u200950 copies\/mL and the appearance of viral rebound in course of cART, hence it is related to a poor control of HIV infection in a population of coinfected patients.<\/jats:p>","DOI":"10.1038\/s41598-019-46976-1","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T10:14:59Z","timestamp":1565950499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV\/HBV-coinfected patients on first-line therapy"],"prefix":"10.1038","volume":"9","author":[{"given":"Vincenzo","family":"Malagnino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlotta","family":"Cerva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Maffongelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Teti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5283-1250","authenticated-orcid":false,"given":"Luca","family":"Foroghi Biland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Novella","family":"Cesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"De Masi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Stingone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Armenia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Svicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Salpini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-0333","authenticated-orcid":false,"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,16]]},"reference":[{"key":"46976_CR1","doi-asserted-by":"crossref","unstructured":"Pinchoff, J. et al. Impact of hepatitis B on mortality and specific causes of death in adults with and without HIV co-infection in NYC, 2000\u20132011. Epidemiol Infect, 1\u201311 (2016)","DOI":"10.1017\/S0950268816001801"},{"key":"46976_CR2","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/jvh.12555","volume":"23","author":"R Rajbhandari","year":"2016","unstructured":"Rajbhandari, R., Jun, T., Khalili, H., Chung, R. T. & Ananthakrishnan, A. N. HBV\/HIV coinfection is associated with poorer outcomes in hospitalized patients with HBV or HIV. J Viral Hepatitis 23, 820\u2013829 (2016).","journal-title":"J Viral Hepatitis"},{"key":"46976_CR3","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/infdis\/jit351","volume":"208","author":"G Wandeler","year":"2013","unstructured":"Wandeler, G., Gsponer, T., Bihl, F., Bernasconi, E., Cavassini, M., Kovari, H., Schmid, P., Battegay, M., Calmy, A., Egger, M., Furrer, H., Rauch, A. & Swiss, H. I. V. Cohort Study. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J Infect Dis 208, 1454\u20138 (2013).","journal-title":"J Infect Dis"},{"key":"46976_CR4","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","volume":"360","author":"CL Thio","year":"2002","unstructured":"Thio, C. L. et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360, 1921\u20131926 (2002).","journal-title":"Lancet"},{"key":"46976_CR5","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1097\/QAD.0b013e32831103ad","volume":"22","author":"GM Clifford","year":"2008","unstructured":"Clifford, G. M. et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 22, 2135\u20132141 (2008).","journal-title":"AIDS"},{"key":"46976_CR6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu & European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu & European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370\u2013398 (2017).","journal-title":"J. Hepatol."},{"key":"46976_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","volume":"148","author":"RP Perrillo","year":"2015","unstructured":"Perrillo, R. P., Gish, R. & Falck-Ytter, Y. T. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148, 221\u2013244.e3 (2015).","journal-title":"Gastroenterology"},{"key":"46976_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11904-018-0379-y","volume":"15","author":"JJ Chang","year":"2018","unstructured":"Chang, J. J., Mohtashemi, N. & Bhattacharya, D. Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era. Curr HIV\/AIDS Rep 15, 172\u2013181 (2018).","journal-title":"Curr HIV\/AIDS Rep"},{"key":"46976_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s15010-008-8194-9","volume":"37","author":"G Morsica","year":"2009","unstructured":"Morsica, G. et al. Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features. Infection 37, 445\u2013449 (2009).","journal-title":"Infection"},{"key":"46976_CR10","doi-asserted-by":"publisher","first-page":"e0190592","DOI":"10.1371\/journal.pone.0190592","volume":"13","author":"B Bivigou-Mboumba","year":"2018","unstructured":"Bivigou-Mboumba, B. et al. Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence. PLoS ONE 13, e0190592 (2018).","journal-title":"PLoS ONE"},{"key":"46976_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/infdis\/jir720","volume":"205","author":"HM Chun","year":"2012","unstructured":"Chun, H. M. et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J. Infect. Dis 205, 185\u2013193 (2012).","journal-title":"J. Infect. Dis"},{"key":"46976_CR12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0000000000000142","volume":"66","author":"HM Chun","year":"2014","unstructured":"Chun, H. M. et al. HIV outcomes in Hepatitis B virus coinfected individuals on HAART. J. Acquir. Immune Defic. Syndr. 66, 197\u2013205 (2014).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"46976_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/cid\/cix747","volume":"66","author":"G-M Kouam\u00e9","year":"2018","unstructured":"Kouam\u00e9, G.-M. et al. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication. Clin. Infect. Dis 66, 112\u2013120 (2018).","journal-title":"Clin. Infect. Dis"},{"key":"46976_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/cid\/cis908","volume":"56","author":"MD Witt","year":"2013","unstructured":"Witt, M. D. et al. Predictors of the isolated hepatitis B core antibody pattern in HIV-infected and -uninfected men in the multicenter AIDS cohort study. Clin. Infect. Dis 56, 606\u2013612 (2013).","journal-title":"Clin. Infect. Dis"},{"key":"46976_CR15","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1097\/QAI.0000000000000941","volume":"72","author":"D Bhattacharya","year":"2016","unstructured":"Bhattacharya, D. et al. Isolated Hepatitis B Core Antibody is Associated With Advanced Hepatic Fibrosis in HIV\/HCV Infection But Not in HIV Infection Alone. J. Acquir. Immune Defic. Syndr. 72, e14\u201317 (2016).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"46976_CR16","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1097\/QAD.0000000000001574","volume":"31","author":"KP Singh","year":"2017","unstructured":"Singh, K. P. et al. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS 31, 2035\u20132052 (2017).","journal-title":"AIDS"},{"key":"46976_CR17","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/nm1511","volume":"12","author":"JM Brenchley","year":"2006","unstructured":"Brenchley, J. M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365\u20131371 (2006).","journal-title":"Nat. Med."},{"key":"46976_CR18","first-page":"328","volume":"4","author":"JD Debes","year":"2016","unstructured":"Debes, J. D., Bohjanen, P. R. & Boonstra, A. Mechanisms of Accelerated Liver Fibrosis Progression during HIV Infection. J Clin Transl Hepatol 4, 328\u2013335 (2016).","journal-title":"J Clin Transl Hepatol"},{"key":"46976_CR19","first-page":"118","volume":"17","author":"SG Deeks","year":"2009","unstructured":"Deeks, S. G. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 17, 118\u2013123 (2009).","journal-title":"Top HIV Med"},{"key":"46976_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1120-8","volume":"15","author":"J Young","year":"2015","unstructured":"Young, J. et al. Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. BMC Infect. Dis. 15, 382 (2015).","journal-title":"BMC Infect. Dis."},{"key":"46976_CR21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/00002030-200203080-00013","volume":"16","author":"AL Moore","year":"2002","unstructured":"Moore, A. L. et al. Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS 16, 615\u2013618 (2002).","journal-title":"AIDS"},{"key":"46976_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jcv.2004.11.012","volume":"33","author":"B Masquelier","year":"2005","unstructured":"Masquelier, B. et al. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J. Clin. Virol. 33, 75\u201378 (2005).","journal-title":"J. Clin. Virol."},{"key":"46976_CR23","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/infdis\/jis104","volume":"205","author":"JT Grennan","year":"2012","unstructured":"Grennan, J. T., Loutfy, M. R. & Su, D. et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J InfectDis 205, 1230\u20138 (2012).","journal-title":"J InfectDis"},{"key":"46976_CR24","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.bulm.2005.01.006","volume":"67","author":"LE Jones","year":"2005","unstructured":"Jones, L. E. & Perelson, A. S. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART. Bull. Math. Biol. 67, 1227\u20131251 (2005).","journal-title":"Bull. Math. Biol."},{"key":"46976_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1086\/315260","volume":"181","author":"HF G\u00fcnthard","year":"2000","unstructured":"G\u00fcnthard, H. F. et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J. Infect. Dis. 181, 522\u2013531 (2000).","journal-title":"J. Infect. Dis."},{"key":"46976_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<323::AID-JMV11>3.0.CO;2-P","volume":"59","author":"M Grzywacz","year":"1999","unstructured":"Grzywacz, M. et al. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g\/day or 6 g\/day in HIV-infected patients. J. Med. Virol. 59, 323\u2013328 (1999).","journal-title":"J. Med. Virol."},{"key":"46976_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/infdis\/jiu417","volume":"211","author":"M Lichtner","year":"2015","unstructured":"Lichtner, M. et al. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J. Infect. Dis. 211, 178\u2013186 (2015).","journal-title":"J. Infect. Dis."},{"key":"46976_CR28","first-page":"490","volume":"64","author":"H Kovari","year":"2017","unstructured":"Kovari, H. et al. Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study. Clin. Infect. Dis. 64, 490\u2013497 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"46976_CR29","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1086\/520989","volume":"45","author":"JI Tsui","year":"2007","unstructured":"Tsui, J. I. et al. Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women. Clin. Infect. Dis. 45, 736\u2013740 (2007).","journal-title":"Clin. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46976-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46976-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46976-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:43:12Z","timestamp":1671280992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46976-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["46976"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-46976-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2019,8,16]]},"assertion":[{"value":"14 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare they have no conflicts of interest related to this manuscript. However, MA has received founds for attending symposia, speaking, grant research support, consultancy and advisory board membership from ABBOT, BRISTOL, GILEAD, MERCK, JANSENN CILAG, PFIZER, ROCHE, and ViiV HEALTHCARE. LS has received founds for attending symposia, speaking, and grant research support from GILEAD, MERCK, JANSENN CILAG, PFIZER, and ViiV HEALTHCARE.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11942"}}